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H I G H L I G H T S
• Double transglutaminase 2 and Factor XIII-A knockout exacerbates cardiac fibrosis.• Double knockout does not promote the growth of, or destabilise, brachiocephalic plaques.• FXIII-A in resident cardiac macrophages does not protect against cardiac fibrosis.• FXIII-A in inflammatory macrophages may contribute to protection against fibrosis.• Transglutaminase 2 and Factor XIII-A protect against extravasation of blood.







A B S T R A C T
Background and aims: Transglutaminase (TG) 2 and Factor (F) XIII-A have both been implicated in cardiovas-
cular protection and repair. This study was designed to differentiate between two competing hypotheses: that
TG2 and FXIII-A mediate these functions in mice by fulfilling separate roles, or that they act redundantly in this
respect.
Methods: Atherosclerosis was assessed in brachiocephalic artery plaques of fat-fed mixed strain apolipoprotein
(Apo)e deficient mice that lacked either or both transglutaminases. Cardiac fibrosis was assessed both in the
mixed strain mice and also in C57BL/6J Apoe expressing mice lacking either or both transglutaminases.
Results: No difference was found in the density of buried fibrous caps within brachiocephalic plaques from mice
expressing or lacking these transglutaminases. Cardiac fibrosis developed in both Apoe/F13a1 double knockout
and F13a1 single knockout mice, but not in Tgm2 knockout mice. However, concomitant Tgm2 knockout
markedly increased fibrosis, as apparent in both Apoe/Tgm2/F13a1 knockout and Tgm2/F13a1 knockout mice.
Amongst F13a1 knockout and Tgm2/F13a1 knockout mice, the extent of fibrosis correlated with hemosiderin
deposition, suggesting that TG2 limits the extravasation of blood in the myocardium, which in turn reduces the
pro-fibrotic stimulus. The resulting fibrosis was interstitial in nature and caused only minor changes in cardiac
function.
Conclusions: These studies confirm that FXIII-A and TG2 fulfil different roles in the mouse myocardium. FXIII-A
protects against vascular leakage while TG2 contributes to the stability or repair of the vasculature. The pro-
tective function of TG2 must be considered when designing clinical anti-fibrotic therapies based upon FXIII-A or
TG2 inhibition.
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1. Introduction
Transglutaminases (TGs) comprise a family of 8 enzymes that cat-
alyse the Ca2+-dependent formation of Nε (γ-glutamyl) lysine isopep-
tide cross-links between and within protein chains [1].
TG2, which is also known as tissue transglutaminase, is expressed in
all cell-types and in all tissues, but its expression increases under con-
ditions of stress [2]. Within the cell, TG2 is primarily cytosolic, but
separate pools of TG2 exist in the nucleus, endosomes and associated
with mitochondria [2]. Although its catalytic activity is strongly sup-
pressed by low Ca2+ concentrations and a high [GTP]/[GDP ratio] [1],
TG2 has nevertheless been implicated in intracellular signalling [3].
TG2 can also be secreted from the cytosol onto the cell-surface and into
the extracellular matrix [4]. Here, in the reduced form [5], TG2 cross-
links matrix proteins including collagen I chains [4]. Once oxidised,
TG2 functions instead as a structural protein [6,7]. Despite various roles
previously attributed to TG2, the Tgm2 knockout mouse obtained by
Iismaa and Graham develops normally but shows an impaired response
to stress or injury [8,9]. For example, Tgm2 knockout compromises the
inward arterial remodelling that occurs in response to flow restriction
[10].
The consequences of TG2 deficiency in humans are unknown.
However, it has been suggested that TG2-mediated cross-linking occurs
predominantly in damaged or ageing human tissues [11]. Amongst
affected tissues, TG2 is strongly expressed in human atherosclerotic
plaques, where it may contribute to plaque stability. However, neither
we [12] nor Van Herck et al. [13] observed any difference in the rate of
plaque rupture when comparing Apoe/Tgm2 knockout mice with Apoe
knockout mice.
Blood clotting factor FXIII-A is present as a dimer within the cytosol
of megakaryocytes, platelets and resident macrophages of the heart,
arteries, lung and placenta [14]. Resident macrophages mediate the
release of FXIII-A into the plasma [15], where it circulates as a het-
erotetrameric zymogen complex with the non-catalytic B-subunit. Fol-
lowing activation by thrombin, FXIII-A cross-links proteins including
fibrin and α-2 antiplasmin within blood clots [16] and fibronectin
within the extracellular matrix of injured tissues. Deficiency of FXIII-A
in human subjects predisposes to cerebral haemorrhage and haemor-
rhage during pregnancy.
Fatal haemorrhage occurs spontaneously in male F13a1 knockout
mice [17]. and also in pregnant female F13a1 knockout mice [18]. Non-
fatal myocardial bleeds also occur in F13a1 knockout mice and result in
the extravasation of red blood cells into the myocardium [17]. Thus,
together with tissue factor and clotting factor VII [19,20], FXIII-A may
establish a haemostatic barrier that protects cardiac blood vessels
against extravasation under the mechanical stress of beating and re-
duces the consequent development of fibrosis [19]. Other studies have
reported that FXIII-A reduces the permeability of the vasculature [21],
but it remains unclear how this observation relates to its protective role
against extravasation and fibrosis in myocardial vessels.
Fibrosis is classified as two major types. Replacement fibrosis occurs
when collagen deposition forms a scar to fill and stabilise a region
within which cells have died, for example the ischaemic area of an
infarcted heart [22]. In contrast, interstitial fibrosis results from in-
creased deposition of collagen between living cells, for example
amongst cells peripheral to an infarct following a myocardial infarction
[22]. Fibrosis is poorly reversible, and in the heart it predisposes to
ventricular dysfunction and poorer clinical outcomes [23,24]. There-
fore, it would be desirable to limit the extent of fibrosis to reparative
scar formation only and minimise the involvement of adjacent healthy
tissue. Various stimuli may induce fibrosis following infarction, in-
cluding the presence of blood within the myocardium [23,24]. TG2
promotes the response to fibrotic stimuli by several proposed me-
chanisms that involve the profibrotic mediator TGF-β.25These me-
chanisms may include activating the TGF-β precursor complex in the
extracellular matrix [25], and directly potentiating the effect of TGF-β
signalling on cardiofibroblasts [26]. Consequently, in model systems
including the heart [26], TG2 inhibition reduces fibrosis.
Previous studies have suggested that FXIII-A and TG2 act re-
dundantly to mediate functions including arterial remodelling [10] and
bone deposition [27]. To investigate potential redundancy, we [21] and
Mousa et al. [28] have previously generated mice that are knockouts for
both transglutaminases. In this work, we have used mice lacking either
or both transglutaminases to determine whether FXIII-A and TG2 act
redundantly to stabilise atherosclerotic plaques. We have also used
these mice to investigate whether concomitant Tgm2 knockout reduces
fibrosis in the F13a1 knockout mouse, as might be predicted if TG2
promotes fibrosis in response to extravasated blood.
2. Materials and methods
2.1. Maintenance of mouse lines
Animal husbandry and procedures were conducted in accordance
with guidelines and regulations of the United Kingdom Home Office
and of the Universities of Bristol (studies on mixed strain mice) and
Leeds (studies on C57BL/6J mice). Mice had free access to food and
water, except for limited periods when food was withheld for glucose or
insulin tolerance testing.
2.2. Generation of mixed strain Apoe knockout mice deficient in F13a1
and/or Tgm2
Mixed strain F13a1−/− mice [29] were obtained from Harlan La-
boratories, Rossdorf, Germany, from a stock bred in recent generations
from homozygous knockout females [30]. Apoe−−/−/Tgm2−/− mice
on a mixed (C57BL/6J x 129) background [12] were crossed with male
mixed strain F13a1−/− mice to generate F1 triple heterozygous mice.
Interbreeding the F1 mice generated F2 mice including the following
genotypes: Apoe−−/−/Tgm2+/+/F13a1+/− and Apoe−−/−/Tgm2+/
−/F13a1+/−. Interbreeding the F2 Apoe−−/−/Tgm2+/+/F13a1+/−
mice generated littermates to examine the effect of FXIII-A deficiency
on a TG2 expressing background, while interbreeding the Apoe−−/
−/Tgm2+/−/F13a1+/− resulted in FXIII-A deficiency on a TG2-null
background.
2.3. Generation of Apoe expressing C57BL/6J mice deficient in F13a1 and/
or Tgm2
F13a1 knockout mice on a C57BL/6J background [15] were bred
from F13a1+/− dams mated either with F13a1+/− or F13a1−/− sires,
since, in agreement with previous findings [18], each of four pregnant
C57BL/6J F13a1 knockout mice suffered prenatal or perinatal mor-
tality. C57BL/6J F13a1−/− pups from these crosses were born below
Mendelian expectation (226 observed, 325 expected, p < 0.001).
C57BL/6J Tgm2+/− mice [31] were obtained from a colony main-
tained as heterozygotes at the Victor Chang Cardiovascular Research
Institute Darlinghurst, Australia. C57BL/6J Tgm2+/− mice were
crossed with C57BL/6J F13a1+/− mice to generate Tgm2+/−/F13a1+/
− double heterozygous mice and, by further breeding, littermate
Tgm2−/−/F13a1−/− (double knockout), Tgm2+/+/F13a1−/− (F13a1
knockout), Tgm2−/−/F13a1+/+ (Tgm2 knockout) and Tgm2+/
+/F13a1+/+ (wild-type, WT) mice. C57BL/6J Tgm2−/−/F13a1−/−
pups were also born below Mendelian expectation (246 observed, 331
expected p < 0.01), while Tgm2−/− mice were born in accordance
with Mendelian expectation (80 obtained, 88 expected). Oligonucleo-
tides for genotyping are shown in Supplementary Table 1.
C57BL/6J F13a1flox/flox mice (floxed in coding exon 7 of the F13a1
gene) and progeny from crosses with C57BL/6J Pf4-cre and Cd11b-cre
recombinase-expressing mice, were as described previously [15].
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2.4. Fat feeding
In an initial study (1), 30 male mixed strain Apoe knockout mice
(age 6–8 weeks) of each transglutaminase genotype, were maintained
on a high-fat rodent diet containing 21% lard and 0.15% cholesterol
(SDS, Witham, Essex, UK) for 12 weeks. In a follow-up study (2), se-
parate male and female groups of C57BL/6J Apoe expressing mice
(n = 6 or 7) per transglutaminase genotype) were maintained either on
the same high-fat rodent diet or on a standard chow diet for 12 weeks.
2.5. Assessment of atherosclerosis and fibrosis
Mice were anaesthetised either by intraperitoneal injection of so-
dium pentobarbital (20 mg, Rhone Merieux, Harlow, UK), or by in-
halation of 2.5% isoflurane (Zoetis, UK). Blood samples were taken,
then mice were exsanguinated. For study (1), mice were perfusion-fixed
at arterial pressure using 10% buffered formalin, and then the hearts
and brachiocephalic arteries were excised. For study (2), mice were
exsanguinated via the vena cava, and the intact heart was excised while
beating and immersed in phosphate buffered saline containing 4%
paraformaldehyde.
To assess atherosclerosis, paraffin sections (3 μm) were taken 60 μm
from the ostium of the brachiocephalic artery, and also from the first
appearance of all three valve leaflets at the aortic sinus. Serial sections
were stained with elastin Van Gieson (EVG) and haematoxylin and
eosin (H&E) for analysis of plaque morphometry, picrosirius red (S) for
the analysis of collagen and with toluidine blue to detect acidic pro-
teoglycans. To assess myocardial fibrosis, heart ventricle sections from
4 separate transverse planes were stained for collagen deposition using
Masson's trichrome stain and picrosirius red, and with Perls' Prussian
blue stain to assess hemosiderin deposition. In study (2), where the
hearts were not punctured prior to excision, sections from 5 separate
transverse planes across the ventricles were analysed for the presence of
fibrosis and haemosiderin and results from each plane were combined
to determine the fractional affected areas per mouse.
In some cases, rehydrated paraffin sections were subjected to an-
tigen retrieval by boiling in 10 mM citrate buffer pH 6.0. For activated
macrophage detection, sections were quenched in 1% H2O2 in methanol
for 30 min, blocked with rabbit serum, then incubated at 4 °C overnight
in biotinylated Griffonia Simplicifolia lectin I isolectin B4 (GSA 1B4,
10 μg/mL Vector Laboratories Inc.) prior to detection using the
Vectastain ABC kit (Vector Laboratories Inc). For TGF-β detection,
sections were washed in 0.05% PBS-Tween, quenched in 1% H2O2,
incubated in 4% goat serum for 30 min, washed and incubated with a
1:100 dilution of TGF-β1 antibody (NBP2-22114) plus a ‘mouse-on-
mouse’ blocking reagent (ab64259) for 60 min. Slides were washed and
the mouse specific HRP/DAB Detection Kit (ab64259) was applied ac-
cording to the manufacturer's instruction.
2.6. Image analysis
Tissue sections from the mice were imaged using a QICAM Fast
1394 camera (Qimaging, Surrey, BC, Canada) and analysed using
Image-Pro Plus software (Media Cybernetics, Carlsbad, CA, USA) or
using an Olympus BX61WI inverted microscope with an XC10-IR
camera under the control of CellSens software (Olympus). Image ana-
lysis was carried out in a blinded manner.
To determine the distribution of collagen fibres, tissue sections that
had been stained with picrosirius red, were examined using a Zeiss 710
multiphoton microscope (Zeiss). Excitation was achieved at wavelength
of 800–860 nm using a Chameleon laser, and the second harmonic
signal characteristic of collagen fibres, was collected at 400 nm onto a
Zeiss LSM NDD R2 detector (Zeiss), through a 10x objective lens and an
EF SP 485 IR++ filter. Collagen images were merged with brightfield
images of cell nuclei.
2.7. Real time-PCR (RT-PCR)
Hearts or aortas were disrupted in TRIzol (ThermoFisher Scientific)
using a TissueLyser II (Qiagen), RNA was precipitated from the aqueous
layer using 100% ethanol and DNA removed using the “DNA-free” kit
(ThermoFisher Scientific), prior to cDNA synthesis using the High
Capacity Reverse Transcription Kit (ThermoFisher Scientific). RT-PCR
amplification was performed using the primer pairs shown in
Supplementary Table 2 and cycling conditions of 95 °C for 10 min, 45
cycles of 95 °C for 10 s, 60 °C for 1 min. A melting curve was undertaken
to ensure that each reaction had generated a single product and in re-
presentative cases, the products of RT-PCR reactions were resolved by
agarose gel electrophoresis to verify that they were of the expected size.
Transcript levels were normalised to the housekeeper mRNA (Rpl32)
using the 2−ΔCt method [32].
2.8. Statistics
All data is presented as mean ± 2x standard error. All values were
analysed using Prism 7 (GraphPad software, San Diego, CA, USA).
Comparisons between each group were carried out using unpaired
student t-tests (with Welch's correction) or one-way ANOVA (with
Bonferroni correction) for multiple groups. A Kruskal-Wallis test with
Dunn's multiple comparison test was used for any data that were not
normally distributed; normality was assessed using Shapiro Wilk's
testing. Mortality rates and breeding frequencies were analysed using a
Chi-squared test. Significance was accepted where p < 0.05.
3. Results
The results obtained from the various studies below are summarised
in Supplementary Table 3.
3.1. Fat-feeding is associated with increased mortality in mixed strain, Apoe
knockout mice that are deficient in FXIII-A
To determine whether FXIII-A and TG2 act redundantly to influence
plaque development and stability, transglutaminase knockout mice
were crossed with Apoe knockout mice and subjected to a 12 week
period of fat feeding to induce atherosclerosis.
Unexpectedly, mortality over the feeding period was increased in
both Apoe/F13a1 double knockout (5/38, p = 0.02) and Apoe/Tgm2/
F13a1 triple knockout mice (8/39, p = 0.007) relative to Apoe
knockout mice (1/49). Mortality was not increased in Apoe/Tgm2
double knockout mice (1/46). Body weights of mice at 6–8 weeks of age
were similar between genotypes. Final body weights were lower in
Apoe/Tgm2 double knockout and Apoe/Tgm2/F13a1 triple knockout
mice (Supplementary Figure I). As expected, plasma levels of total
cholesterol increased in fat-fed Apoe knockout mice of all genotypes. In
addition, there was an unanticipated additional increase in HDL cho-
lesterol in Apoe/Tgm2 double knockout and Apoe/Tgm2/F13a1 triple
knockout mice which was accompanied by a decrease in plasma tria-
cylglycerols. (Supplementary Figure II).
3.2. Atherosclerotic plaque stability is unaffected in mixed strain Apoe
knockout mice that are also deficient both in FXIII-A and TG2
Atherosclerosis was assessed at two independent sites in mice that
had survived fat-feeding: brachiocephalic artery plaques which show
features of advanced atherosclerosis and mouse aortic retrovalvular
sinus plaque lesions which develop as simple xanthomas.
Brachiocephalic plaques of Apoe/Tgm2/F13a1 triple knockout mice
showed a 28% decrease in cross-sectional area compared to Apoe
knockout controls (p = 0.047) but plaque area was unaltered in both
Apoe/F13a1 and Apoe/Tgm2 knockout mice (Table 1). Acidic pro-
teoglycan deposition (indicating areas of chondrocytic metaplasia
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which can progress to calcification), was also reduced within plaques of
Apoe/Tgm2/F13a1 knockout mice (Table 1), suggesting that the smaller
plaques had not advanced as far as the plaques in other genotypes. The
frequency of buried fibrous caps per unit plaque area (an index of the
rate of plaque rupture) [33] did not differ across the groups (Table 1).
However, plaque collagen content was reduced by 30% in Apoe
knockout mice lacking either TG2, or, both TG2 and FXIII-A. Staining
with GSA 1B4 showed no difference in the density of activated mac-
rophages between plaques from mice of different genotypes.
We also examined atherosclerosis in the aortic sinus. However, al-
though it has been observed that knockout of TG2 within macrophages
increases lesion size at this site [34], no statistically significant differ-
ences between genotypes were observed in size or composition of aortic
sinus plaques (Table 1).
3.3. Cardiac fibrosis due to FXIII-A deficiency is exacerbated, rather than
reduced, by concomitant TG2 deficiency in Apoe knockout mice
TG2 is profibrotic in various models [25]. We therefore measured
fibrosis in the hearts of mice that survived the 12 week fat-feeding
period to determine whether Tgm2 knockout decreased the fibrotic
response associated with F13a1 knockout.
Contrary to expectation, 3/30 Apoe/F13a1 double knockout mice
and 20/28 Apoe/Tgm2/F13a1 triple knockout mice showed myocardial
fibrosis (p < 0.0001, Fig. 1A). Further, the extent of ventricular fi-
brosis was less in the three affected Apoe/F13a1 double knockout mice
(4.0 ± 0.5%) than in the 20 affected Apoe/Tgm2/F13a1 triple
knockout mice (17.8 ± 9.4%, p < 0.01). The percentage fibrotic area
per ventricle (Fig. 1B), averaged across both fibrotic and non-fibrotic
mice of each genotype, increased approximately 30-fold between the
Apoe/Tgm2/F13a1 triple knockout mice and the Apoe/F13a1 double
knockout mice. The presence of haemosiderin within the fibrotic
myocardium (Fig. 1C) suggested that extravasation of red blood cells
had occurred.
3.4. Cardiac fibrosis due to FXIII-A deficiency is exacerbated by
concomitant TG2 deficiency in C57BL/6J Apoe expressing mice
Traits associated with gene knockout may be expressed variably in
mice of different genetic backgrounds [35,36]. To confirm that Tgm2
knockout exacerbated the fibrosis associated with F13a1 knockout, and
might therefore provide a reproducible model of fibrosis, we repeated
the study using mice on a defined C57BL/6J background. These mice
were either recently derived (F13a1 knockout), or had been maintained
as heterozygotes (Tgm2 knockout), to avoid the selection of modifying
traits. These mice also expressed Apoe to avoid possible effects of Apoe
knockout upon, for example, vascular permeability [37] or macrophage
survival [38,39].
In contrast to the mixed strain Apoe/Tgm2/F13a1 triple knockout or
Apoe/F13a1 double knockout mice, spontaneous deaths did not occur
amongst either the C57BL/6J F13a1 single knockout or Tgm2/F13a1
double knockout mice, whether on a high fat or chow diet. No sig-
nificant differences in body weight gain or plasma metabolite levels
were apparent between genotypes at termination (Supplementary
Figures I and II.)
Cardiac fibrosis was apparent in C57BL/6J F13a1 knockout and in
C57BL/6J Tgm2/F13a1 double knockout mice, but not in Tgm2
Table 1
Atherosclerotic plaque morphometry in mixed strain Apoe knockout mice deficient in transglutaminases TG2 and or FXIII-A.
Parameter Apoe−/-(n = 30) Apoe−/-/F13a1−/−(n = 28) Apoe−/-/Tgm2−/−(n = 30) Apoe−/-/Tgm2−/
−/F13a1−/−(n = 27)
Brachiocephalic artery Plaque area (x 103 μm2) 106 ± 8 106 ± 7 102 ± 7 76 ± 10*
Buried fibrous caps (per mm2 plaque area) 14.8 ± 2.4 13.8 ± 1.7 12.5 ± 3.2 11.5 ± 2.5
Elastin content (%) 17.2 ± 1.6 13.1 ± 1.9 11.0 ± 1.2 13.0 ± 2.2
Lipid content (%) 13.9 ± 1.6 11.7 ± 1.8 16.1 ± 1.6 15.5 ± 2.5
Medial collagen content (%) 18.5 ± 2.7 22.1 ± 3.0 18.0 ± 2.8 11.4 ± 1.6
Plaque collagen content (%) 29.2 ± 2.2 31.2 ± 2.0 21.5 ± 2.1*** 19.6 ± 2.4***
Plaque acidic proteoglycan content (%) 10 ± 2 8 ± 1 9 ± 2 3 ± 1**
Plaque lectin staininga 19.0 ± 3.1 16.7 ± 2.4 21.5 ± 4.0 24.2 ± 3.9
Aortic sinus Vessel area (x 103 μm2) 1284 ± 60 1254 ± 63 1351 ± 51 1239 ± 75
Plaque area (x 103 μm2) 59 ± 5 52 ± 4 65 ± 4 62 ± 6
Elastin content (%) 11 ± 1 10 ± 2 8 ± 1 9 ± 1
Lipid content (%) 6 ± 1 5 ± 1 8 ± 1 9 ± 1
Collagen content (%) 54 ± 5 55 ± 2 54 ± 4 58 ± 1
Acidic proteoglycan content (%) 10 ± 3 10 ± 4 14 ± 4 13 ± 2
Brachiocephalic plaque area (*p < 0.05), content of acidic proteoglycan (**p < 0.01) and collagen (***p < 0.001) differed between genotypes. Other parameters
were unchanged.
a Plaques were stained with Griffonia Simplicifolia lectin I isolectin B4 (GSA 1B4) to detect infiltration of activated macrophages.
Fig. 1. Cardiac fibrosis in Apoe knockout mice deficient in transglutaminases
TG2 and/or FXIII-A.
(A) Representative Masson's (M) trichrome-stained sections of left ventricle wall
from (i) Apoe knockout (KO), (ii) Apoe/F13a1 knockout, (iii) Apoe/Tgm2
knockout, and (iv) Apoe/Tgm2/F13a1 knockout mice. Scale bar represents
100 μm. (B) Quantitation of fibrosis in mice of the various genotypes (n = 30
per genotype, except Apoe/Tgm2/F13a1 knockout where n = 28) determined
by the area of the ventricle stained by Masson's trichrome. (C) Fibrotic heart
section from an Apoe/F13a1 knockout mouse which was stained with Perls'
Prussian blue to detect haemosiderin deposits. Scale bar as in (A). The section
was counterstained with Neutral Red. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this
article.)
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knockout or wild-type mice (Fig. 2A). Cardiac fibrosis at 20 weeks of
age was more extensive in C57BL/6J Tgm2/F13a1 double knockout
mice than in C57BL/6J F13a1 single knockout mice, and in both
genotypes was more extensive in male than in female mice. However,
fibrosis was not increased in mice fed a high-fat diet over chow-fed
mice. Cardiac fibrosis was apparent at 8 weeks of age in some Tgm2/
F13a1 double knockout mice (Fig. 2B). Cardiac pressure-volume loop
measurements were obtained to determine whether fibrosis compro-
mised cardiac function. Tgm2/F13a1 knockout mice fed on standard
chow for 24 weeks, showed an increase in left ventricular stiffness re-
lative to wild-type mice (Fig. 2C), consistent with fibrosis, but in gen-
eral, cardiac function was well preserved (Supplementary Figure III.).
3.5. Additional Tgm2 knockout promotes the development of interstitial
fibrosis secondary to increased extravasation of blood
To determine whether concomitant Tgm2 knockout resulted in
more extensive fibrosis through increasing the extravasation of blood or
by enhancing the fibrotic response to extravasated blood, hemosiderin
was quantified in the myocardia of mice of each genotype (Fig. 2D), and
the relationship between hemosiderin content and fibrosis was de-
termined. Combining data from the F13a1 single and Tgm2/F13a1
double knockout mice revealed that hemosiderin deposition positively
correlated with fibrosis (Fig. 2E), suggesting that the profibrotic effect
of Tgm2 knockout resulted from increased extravasation.
Staining fibrotic myocardia with H&E identified a Tgm2/F13a1
knockout heart where recent vessel damage was evident with escape of
red blood cells (RBCs) at this site (Fig. 3A). To determine whether re-
placement or interstitial fibrosis predominated, sections of Tgm2/F13a1
knockout hearts were stained with picrosirius red and then examined
by dual photon microscopy. The second harmonic signal at 400 nm,
diagnostic for collagen fibres, was apparent within fibrotic regions of 4
hearts that were examined. Elongated nuclei were distributed
throughout the collagen fibres (Fig. 3B). The estimated density of nuclei
within two fibrotic areas in the myocardium of a representative Tgm2/
F13a1 knockout heart (544 nuclei.mm−2) was similar to the density in
adjacent uninvolved regions of that same heart (398 nuclei.mm−2) and
was similar to the density of cells in a representative non-fibrotic wild
type heart (418 nuclei.mm−2), and a single non-fibrotic Tgm2/F13a1
knockout heart (346 nuclei mm−2). Bearing in mind, however, that we
observed some differences in the density of nuclei between individual
Fig. 2. Cardiac fibrosis in Apoe expressing C57BL/6J mice deficient in trans-
glutaminases TG2 and/or FXIII-A.
(A) Representative sections of left ventricle stained with Masson's trichrome
(M) or Picrosirius Red (S) from 20 week old male Apoe+/+ mice of the geno-
types shown that had been maintained on a normal chow diet (NC) or high-fat
diet (HF) for 12 weeks, from 8 weeks of age. Scale bar represents 100 μm. (B)
Quantitation of fibrosis in 5 ventricular sections from the hearts of 8 week old
mice maintained on NC at baseline (B) and then a further 12 weeks of NC or HF
diet (n = 6, except male HF Tgm2/F13a1 knockout mice where n = 7). Fibrosis
was exacerbated in Tgm2/F13a1 double knockout mice as compared to F13a1
knockout mice, and in male mice relative to female mice, (p < 0.05 in each
case). Fibrosis was not detected following 20 weeks of normal-chow feeding in
Pf4-cre.F13a1flox/flox mice of either gender (Pf4-cre, n = 10). Fibrosis was not
detected in Tgm2 knockout or C57BL/6J wild-type mice (not shown). (C) End
diastolic elastance (EDE) values of hearts from C57BL/6J wild-type mice at 24
weeks and from Tgm2/F13a1 double knockout mice at ages 12 and 24 weeks
calculated from the pressure volume parameters shown in Supplementary
Figure III. The development of fibrosis in the Tgm2/F13a1 double knockout
mice was verified post-mortem, and was associated with an increase in EDE. (D)
Haemosiderin deposition in ventricles of mice of the genotypes indicated at
baseline (8 weeks) or after being maintained for a further 12 weeks on either a
normal chow (NC) or a high fat (HF) diet. Haemosiderin content was increased
in both male and female Tgm2/F13a1 double knockout mice (p < 0.05 in each
case). (E) Haemosiderin deposition plotted against the extent of fibrosis in all
male (square) and female (circle) F13a1 knockout and Tgm2/F13a1 double
knockout mice. The extent of fibrosis was positively correlated with haemosi-
derin deposition, (r = 0.7041, p < 0.0001 n = 73). (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web
version of this article.)
Fig. 3. Loss of blood vessel integrity leads to interstitial fibrosis in Apoe ex-
pressing C57BL/6J Tgm2/F13a1 double knockout mice.
(A) H&E stained heart section from a C57BL/6J Tgm2/F13a1 double knockout
mouse. Arrowheads show clusters of red blood cells extravasating into the
myocardium from an apparently damaged epicardial blood vessel. (B)
Representative merged images of collagen (orange) obtained by dual photon
microscopy superimposed on brightfield images (shown in greyscale) from (i) a
C57BL/6J Tgm2/F13a1 double knockout mouse and (ii) a C57BL/6J wild-type
mouse. Elongated nuclei are distributed throughout the fibrotic region in-
dicating a lack of cell death and the presence of predominantly interstitial-type
fibrosis. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
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sections within a single healthy heart, we considered that expressing
the density of nuclei within fibrotic regions (126 ± 28%, n = 4 hearts,
2 fibrotic sections per heart) relative to the density in adjacent to fi-
brotic regions (100%) was the more informative comparison. The si-
milar cell density is consistent with the development of interstitial-ra-
ther than replacement-type fibrosis.
TGF-β1 frequently mediates profibrotic signalling, and has been
implicated in models of cardiac fibrosis [26]. In accord with this, TGF-β
antigen was detectable by immunohistochemistry at the margins of fi-
brotic regions in hearts from F13a1 knockout and Tgm2/F13a1 double
knockout mice, but not in non-fibrotic hearts (Supplementary Figure
IV). However, we cannot exclude the possibility that histochemistry
may have detected the latent precursor complex in addition to active
TGF-β. TGF-β staining in fibrotic hearts was variable, possibly reflecting
the episodic development of fibrosis in response to bleeding. In some
regions, staining was diffuse, consistent with release of TGF-β into the
ECM.
3.6. The phenotype at baseline is similar between control and
transglutaminase knockout mice
While the results above suggest that TG2 limits the extravasation
that results from FXIII-A deficiency, we also investigated whether
knockout of transglutaminases might influence the fibrotic response by
other mechanisms. If this were the case, it would complicate the use of
this model to investigate the response to extravasated blood.
It has been reported that TG2 expression negatively regulates the
transcription of TGF-β1 and collagens I and III mRNA [40,41], in which
case TG2 knockout might increase the expression of each and establish
a profibrotic state. However, expression of transcripts encoding col-
lagens I and III and TGF-β1 were comparable between genotypes in
mice at 8 weeks of age. Transcripts encoding haemoxygenase were
elevated in Tgm2/F13a1 double knockout mice relative to other geno-
types (p < 0.05), which may reflect a response to early bleeding in
these mice, which presumably preceded the onset of fibrosis (Fig. 4A).
We also quantified transcripts encoding other structural proteins, and
enzymes mediating extracellular matrix turnover; none of these showed
a consistent and significant elevation in Tgm2/F13a1 double knockout
mice relative to other genotypes (Fig. 4B). Further, in agreement with
our previous work [30], there was no evidence that induction of TG1 or
TGs 3, 4, 5, 6, and 7 compensated for the absence of FXIII-A and/or TG2
in the C57BL/6J mice (Supplementary Figure V.).
Some [42], but not all [31], reports have suggested that glucose
metabolism is impaired by TG2 knockout, suggesting that metabolic
dysfunction might impact on fibrosis development. We observed that
C57BL/6J Tgm2/F13a1 double knockout mice remained viable up to 40
weeks, and that weight gain was not significantly different from other
genotypes (Supplementary Figure VIA). Insulin and glucose tolerance
were comparable between wild-type and C57BL/6J Tgm2/F13a1 double
knockout mice either at 10 weeks or 40 weeks of age (Supplementary
Figure VIB.). It has also been suggested that transglutaminases facilitate
phagocytosis by macrophages [43], and this could affect the develop-
ment of fibrosis through several pathways. However we observed no
difference using isolated macrophages from wild-type versus C57BL/6J
Tgm2/F13a1 double knockout mice (Supplementary Figure VII).
Noll et al. [21] reported that absence of FXIII-A may increase vas-
cular permeability systemically, which could promote RBC extravasa-
tion in addition to any effect that focal vessel damage might have.
However, while we observed an increase vascular permeability to Evans
Blue dye in C57BL/6J F13a1 knockout mice, we observed no further
increase in C57BL/6J Tgm2/F13a1 double knockout mice, suggesting
that increased permeability is unlikely to contribute to increased ex-
travasation in these mice (Supplementary Figure VIII). Because the
complete survival of C57Bl/6J F13a1 knockout mice differed from the
premature haemorrhagic deaths that occurred in another line of F13a1
knockout mice [17,29], we confirmed that the clotting deficiency in our
C57Bl/6J F13a1 knockout mice was similar to that reported in the
haemorrhagic line [29] (Supplementary Figure IX). This excluded the
possibility that rescue of the clotting deficit accounted for the improved
survival. We also verified that whole blood clotting parameters were
similar between C57Bl/6J F13a1 knockout and Tgm2/F13a1 double
knockout mice, excluding the possibility that Tgm2 present in blood
cells might contribute to clot stability, and that a further decrease in
clot stability in Tgm2/F13a1 double knockout mice might account for
the increase in fibrosis (Supplementary Figure IX).
3.7. FXIII-A within cardiac resident macrophages does not protect against
cardiac fibrosis
FXIII-A is present both as a soluble plasma protein and within cells,
including cardiac macrophages [15]. To determine whether cardiac
Fig. 4. Transcript levels in hearts from Apoe expressing mice deficient in
transglutaminases TG2 and/or FXIII-A.
Levels of transcripts in hearts from 8 week old mice were determined by
quantitative PCR. Transcripts encoding the proteins indicated were normalised
to the housekeeper transcript, Rpl32 mRNA. Averaged levels of each transcript
in transglutaminase knockout mice are shown relative to levels of that tran-
script in C57BL/6J WT mice. (A) Cardiac mRNAs encoding heme oxygenase 1
(Hmox-1), but not collagens I or III or transforming growth factor β1 (Tgf-β),
were elevated in the hearts of Tgm2/F13a1 double knockout mice, (n = 30
control mice, n = 20 transglutaminase knockout mice). (B) Cardiac mRNAs
encoding other transcripts were assayed in the hearts of control (n = 20) and
transglutaminase knockout mice (n = 10). None of these transcripts showed a
significant elevation in the hearts of Tgm2/F13a1 double knockout mice relative
to C57Bl/6J WT mice. (SMA, smooth muscle actin; Mann Rec, C-type mannose
receptor; (MT)-MMP, (membrane type)-matrix metalloproteinase; TIMP, Tissue
inhibitor of matrix metalloproteinases; (t/u)PA, tissue or urokinase type plas-
minogen activator; PAI-1, plasminogen activator inhibitor 1; VWF, von
Willebrand factor; CTGF, connective tissue growth factor).
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macrophage FXIII-A confers protection against fibrosis, we examined
the hearts of (Apoe expressing) Pf4-cre. F13a1flox/flox mice maintained on
a normal chow diet, to determine whether, as in Apoe expressing F13a1
knockout mice, fibrosis was evident. In previous studies, we established
that expression of Pf4-cre abolishes FXIII-A expression within cardiac
resident macrophages of Pf4-cre.F13a1flox/flox mice, whereas conven-
tional myeloid –cre alleles do not [15]. Cardiac fibrosis was un-
detectable in Pf4-cre.F13a1flox/flox mice (Fig. 2B, Supplementary Figure
X), excluding a protective role for FXIII-A in cardiac macrophages, as
well as within platelets which are also depleted of FXIII-A. Plasma FXIII-
A activity is reduced to 20%, in Pf4-cre.F13a1flox/flox mice [15] and it
may therefore be that this reduced plasma pool is sufficient to confer
protection.
4. Discussion
FXIII-A [44] and TG2 [45] are both present within human athero-
sclerotic plaques, where they may cross-link and stabilise the extra-
cellular matrix. FXIII-A also protects against the development of fibrosis
in the mouse heart [17], while TG2 promotes the development of fi-
brosis in several disease models [25]. We have investigated the pro-
tective roles of these two transglutaminases in transglutaminase
knockout mice.
Previously, neither we [12] nor Van Herck et al. [13] observed any
alteration in the density of buried caps in brachiocephalic plaques in
mixed strain Apoe/Tgm2 knockout mice relative to Apoe knockout mice,
suggesting that the rate of plaque rupture was the same in both geno-
types. Here, we have further shown that the density of buried caps is
unaltered in male Apoe/Tgm2/F13a1 knockout mice relative to Apoe
knockout mice. Despite this, and in agreement with Van Herck et al.
[13] we observed that collagen (which stabilises human plaques [46])
is decreased in brachiocephalic plaques from Apoe-deficient Tgm2
knockout and Tgm2/F13a1 double knockout mice. Thus, while neither
FXIII-A nor TG2 is required to generate new caps, or, in the short term,
to stabilise existing caps, TG2 may yet prove protective [46,47], pos-
sibly through its ability to cross-link collagen I chains [4]. It is possible
that expression of another transglutaminase is induced within the
brachiocephalic plaque to compensate for the absence of FXIII-A or
TG2. While we have not seen evidence for compensation in aortas
(Griffin et al., in preparation) or within other tissues [30,31], we cannot
exclude compensation in the brachiocephalic artery. However, the
disparate activation mechanisms of the various transglutaminases [1],
make the possibility of compensation seem unlikely.
Souri et al. [17] observed that male F13a1 knockout mice deposit
haemosiderin and develop cardiac fibrosis, suggesting that FXIII-A
contributes to the haemostatic barrier in the cardiac vasculature. The
mechanism of protection is uncertain, but is unlikely to be a result of
cross-linking fibrin, since fibrinogen knockout mice do not develop fi-
brosis [19]. We detected mild cardiac fibrosis in a small proportion of
fat-fed Apoe/F13a1 double knockout mice, and extensive fibrosis in the
majority of Apoe/Tgm2/F13a1 triple knockout mice. To confirm that
concomitant Tgm2 knockout exacerbates fibrosis, we bred F13a1
knockout and Tgm2/F13a1 double knockout mice, each upon a defined
C57BL/6J background. We confirmed that fibrosis was exacerbated in
Tgm2/F13a1 knockout mice relative to F13a1 single knockout mice and
have further shown that fibrosis was increased in male mice relative to
female mice.
Imaging fibrotic regions in the C57BL/6J Tgm2/F13a1 double
knockout mice showed that interstitial, rather than replacement, fi-
brosis predominated. While interstitial fibrosis can impair electrical
signalling in the heart [48], cardiomyocytes within the affected region
would nevertheless be expected to remain viable and contractile. In
agreement with this, pressure volume loop measurements indicated
that cardiac function was generally well preserved in the C57BL/6J
Tgm2/F13a1 double knockout mice, but with an increase in end dia-
stolic elastance, consistent with ventricular stiffening. The presence of
fibrillar collagen in the fibrotic regions suggests that collagens I and III
will predominate, although further work will be required to verify this.
We detected haemosiderin in the fibrotic myocardia of both Apoe/
Tgm2/F13a1 triple knockout and C57BL/6J Tgm2/F13a1 double
knockout mice. While this strongly suggests that red blood cells had
extravasated and been engulfed by macrophages, a small fresh bleed
was detected in the myocardium of only one Tgm2/F13a1 double
knockout mouse. Presumably, frequent or significant bleeds would have
proved fatal. In contrast, we detected extensive cardiac haemorrhage at
termination in a single mouse from the Apoe/Tgm2/F13a1 triple
knockout line, (Supplementary Figure XIA), amongst which premature
deaths occurred. Extravasation of blood cells might occur either be-
cause the cardiac vasculature showed increased permeability
throughout its length or because discrete breakages had caused leakage
from the vasculature. The second possibility is supported by the de-
tection of leakage from a damaged blood vessel in a Tgm2/F13a1
double knockout mouse. Such intermittent bleeding would be expected
to cause fibrosis to develop episodically, which is consistent with the
finding of macrophage invasion in 5 of 25 Apoe/Tgm2/F13a1 hearts
examined (Supplementary Figure XIB). Similarly TGF-β staining varied
between fibrotic regions, which is again consistent with episodic de-
velopment. However, it should be noted that immunohistochemistry
may not have confirmed the presence of the active, rather than the
precursor, form of TGF-β.
We observed that haemosiderin deposition generally correlated
with fibrosis in the F13a1 knockout and Tgm2/F13a1 double knockout
mice, (with the constraint that a recent bleed could generate haemo-
siderin prior to fibrosis, whilst an old bleed could have generated fi-
brosis that persisted after the haemosiderin was cleared). This suggests
that the protective role of TG2 involves strengthening the basal struc-
ture of the vessel and/or promoting its repair. We also deduced a role
for TG2 in protecting vessels against mechanical stress from parallel
carotid ligation experiments. Ligation led to the expected outcome of
inward vessel remodelling in Apoe/F13a1 knockout and WT mice.
However, ligation led to vessel rupture in Apoe/Tgm2/F13a1 triple
knockout mice, and to dilatation and elastic lamina breakage without
rupture in Apoe/Tgm2 knockout mice (Supplementary Figure XII.).
Administering plasma FXIII-A protects FXIII-A deficient patients
against haemorrhage [49]. To determine whether plasma FXIII-A also
protects against fibrosis, we recombined the F13a1flox/flox gene using
Pf4-cre which completely ablates FXIII-A expression both within
CD163pos resident cardiac macrophages and within platelets. C57BL/6
Pf4-cre.F13a1 flox/flox mice did not develop fibrosis suggesting that the
residual 20% of plasma FXIII-A, is likely to be protective. However we
cannot completely exclude a role for macrophage FXIII-A in conferring
protection since we detected cardiac fibrosis in a small number of
Cd11b-cre.F13a1flox/flox mice (n = 4), (Supplementary Figure X.), even
though these mice have plasma FXIII-A levels 65% of wild-type [15]. It
is therefore possible that some protection is conferred by FXIII-A within
inflammatory macrophages (the lineage within which Cd11b is strongly
expressed). If so, this may be similar to the role that FXIII-A in in-
flammatory macrophages plays in stabilising scars following myo-
cardial infarction [50]. Further work is required to confirm that the
Cd11b-cre transgene has mediated its effects by suppressing F13a1 ex-
pression, as opposed to exerting off-target effects on other aspects of
monocyte/macrophage function.
Male FXIII-A knockout mice are prone to sudden haemorrhagic
deaths [17] while female mice may haemorrhage during pregnancy
[18]. We observed spontaneous deaths amongst the fat-fed, mixed
strain Apoe/F13a1 double knockout and Apoe/Tgm2/F13a1 triple
knockout mice and, in cases where autopsy was possible, haemorrhage
was confirmed. However, the increase in death rates (1.5-fold) in the
triple knockout mice was much less than the increase in fibrosis (32-
fold). Further, deaths did not occur amongst the C57BL/6J F13a1 or
Tgm2/F13a1 mice post weaning, even up to 40 weeks, despite com-
parable levels of fibrosis in between Apoe/Tgm2/F13a1 triple knockout
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mice and Tgm2/F13a1 mice. It therefore appears that different factors
govern the tendency to small bleeds, which lead to myocardial fibrosis,
as opposed to lethal bleeds. Further, even though adult Apoe/Tgm2/
F13a1 triple knockout mice did not suffer haemorrhage, C57BL/6J
F13a1 knockout pups were born in occasional non-viable litters with
evidence of haemorrhage (Supplementary Figure XIII.), again sug-
gesting that additional background factors affect the vascular pheno-
type associated with FXIII-A deficiency.
In summary, the increase in fibrosis in F13a1 knockout mice that
resulted from concomitant Tgm2 knockout was novel and unexpected,
since TG2 is frequently profibrotic [26,51]. However, it cannot be
concluded that TG2 is anti-fibrotic in this model. It might simply be that
the increased extravasation occurring in double knockout mice has
outweighed any moderating effect on fibrotic response associated with
the absence of TG2.
Since Tgm2 expression is absent from conception, we cannot be
certain whether it has increased extravasation by weakening basal
vessel structure or by compromising repair of damaged tissue. If it is the
latter, then there may be circumstances in which inhibiting TG2 to
reduce the fibrotic response could instead compromise repair and
worsen pathology. Certainly, the inhibition of TG2 would seem to be an
unsuitable strategy to treat fibrosis in response to red cell extravasation,
as occurs after myocardial infarction. It may also be important to ensure
that TG2 inhibitors intended for therapeutic use do not show significant
inhibition of FXIII-A, if FXIII-A does indeed maintain vessel integrity in
damaged or diseased tissues.
Irrespective of this, the reproducible fibrosis that occurs in C57BL/
6J Tgm2/F13a1 knockout mice, with excellent survival and satisfactory
preservation of cardiac function and other metabolic parameters, offers
a robust model to investigate both the toxic effects of red blood cells
within the myocardium and novel therapeutic approaches. Further
studies will address these possibilities.
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